D2D Module 3

Just Released: Free D2D Module on Antipsychotic Prescribing

When optimizing the use of antipsychotic medications, providers need to determine an accurate diagnosis, weigh the harms and benefits of specific antipsychotics, learn how best to taper medications appropriately, and stay informed of current federal regulations around antipsychotic use.  This 1-hour interactive module is part of the Drive to Deprescribe series and is designed to help providers, together with their interdisciplinary teams, develop systematic strategies for rational prescribing, deprescribing, or continuing the use of these medications safely and appropriately. Upon completion, participants can earn CMD Clinical Hours.

Start the Free Module Now

News Release

PALTmed Expresses Grave Concern Over Removal of ACIP Members

Our members have long relied on the ACIP for scientifically rigorous, evidence-based guidance to prevent the spread of vaccine-preventable diseases. This guidance is essential to protecting the lives of our patients, who are among the most vulnerable and medically complex populations in the country. We are concerned that such a sudden change could interfere with and delay important decisions, particularly in light of the critical role vaccines play in safeguarding the health of older adults and individuals with chronic conditions. 

View News Release

Webinar June 24: Newly Approved Treatment in Alzheimer's Disease

Join us for a live webinar on June 24 at 12:00PM EST and be among the first to learn about a newly approved treatment for Alzheimer's disease! In collaboration with Alpha Cognition, this edition will educate on the differentiation of the newly approved treatment based on its underlying technology and mechanism of action, as well as review the treatment's efficacy and safety established from clinical trials and real-world evidence. The speakers, including Michael McFadden, Chief Executive Officer at Alpha Cognition, will enable participants to explore unmet needs in the treatment of Alzheimer's Disease and learn about a new treatment. 
US-ZUNV-00069 V1 

Learn More & Register

Advertisement

 

Advertisement